Current Report · Items 7.01, 8.01, 9.01 · 8-K

Neuropace, Inc.

NPCENASDAQEQUITYCurrent

Regulation FD Disclosure · Other Events

Filed Apr 2, 2025Accepted Apr 2, 2025, 4:38 PM EDTCIK 1528287Accession 0001193125-25-071399

Company context

Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Current securities

NPCENASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 7.01, 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On April 2, 2025, NeuroPace, Inc. (the “Company) issued a press release announcing, among other matters, the reaffirming of guidance for fiscal year 2025. A copy of the press release is attached hereto and furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 7.01 and Exhibit 99.1 hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01Item 8.01 - Other Events

Item 8.01 Other Events. On April 2, 2025, the Company issued a press release announcing, among other things, an update on its business plans, including the strategic focusing of its product portfolio on its core, differentiated RNS System product line. As a result, the Company notified DIXI Medical USA Corp. (“DIXI”) on March 27, 2025 that it would not seek to renew the exclusive distribution agreement for U.S. sales of DIXI products, resulting in its expiration on September 30, 2025. During the six-month period following expiration of the agreement, the Company has the right to sell any DIXI product inventory that it holds on the date of expiration.

Filed exhibits (1)

EX-99.1 (by filename) d949067dex991.htm

EX-99.1 2 d949067dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NeuroPace Announces Refocusing of Product Portfolio - Beginning of Wind Down of Stereo EEG (SEEG) Distribution Relationship in Q4 2025 - - Maintaining 2025 Revenue Guidance - - No Change to Long-Range Plan Expectations of Cash Flow Breakeven by the end of 2027 and Achievement of 20%+ Revenue CAGR - Mountain View, Calif. - April 2, 2025 - NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported that as part of a strategic refocusing of its product portfolio on its core, differentiated RNS System product line, it is terminating its distribution relationship for SEEG products and will begin winding down the relationship in the fourth quarter of 2025 and continuing through the first quarter of 2026. “While we believe that entering into the exclusive distribution agreement with DIXI Medical three years ago was appropriate for NeuroPace at the time, our core growth strategy today has evolved significantly from when the distribution agreement began. We believe that, beginning in 2026, our goals will be best and most efficiently served by havi…

Open exhibit ↗

Get the free weekly BCS email.